<DOC>
	<DOCNO>NCT00579124</DOCNO>
	<brief_summary>This pilot study 2 stratum evaluate engraftment graft vs. host disease ( GVHD ) patient receive unrelated partially match relate donor peripheral stem cell use CliniMACS system positively deplete T cell prevent severe GVHD . Feasibility test , focus engraftment , treatment-related mortality ( specific focus interstitial pneumonitis ) severe GVHD .</brief_summary>
	<brief_title>CHP 834 Unrelated Partially Matched Related Donor Peripheral Stem Cell Transportation T B Cell Depletion</brief_title>
	<detailed_description>PRIMARY HYPOTHESIS : T cell depletion utilize CliniMACS device allow precise , specific control graft engineering peripheral blood stem cell unrelated partially match related donor without increase relapse graft rejection grade III IV acute graft vs. host disease ( GVHD ) . SECONDARY HYPOTHESIS : Use CliniMACS device allow define level T cell depletion reflect risk severe GVHD donor/recipient pair . Thus , patient relatively low risk severe GVHD assign Stratum 1 receive graft less T cell depletion define level reinfused T cell . Patients high risk severe GVHD perceive clinical benefit GVHD assign Stratum 2 receive T cell-depleted graft . Conditioning patient ( except immunodeficiency ) include : - Thiotepa 5 mg/kg day 2 day - Cyclophosphamide 60 mg/kg day 2 day - Total body irradiation 200 cGy give twice day 3 day Following condition patient 's receive stem cell process use CliniMACS device . This process do stem cell laboratory The Children 's Hospital Philadelphia . The Stem Cell Lab accredit Foundation Accreditation Cellular Therapy ( FACT ) maintain complete standard operating procedure ( SOP 's ) procedure record . Processing cell use CliniMACS occur accordance Investigator Brochure Technical Manual follow laboratory SOPs use aseptic technique . The CHOP Stem Cell Lab extensive prior experience automate cell processing technology , include CellPro Ceprate device Isolex 300i .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>As October 2014 study close enrollment malignant diseases . This study remain open : Nonmalignant disease : 1 . Bone marrow failure , include severe aplastic anemia 2 . Immunodeficiencies 1 . Patients prior stem cell transplant ( SCT ) bone marrow transplant ( BMT ) exclude study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Blood Marrow Transplant</keyword>
	<keyword>T cell Depletion</keyword>
	<keyword>Unrelated</keyword>
	<keyword>Related</keyword>
	<keyword>Donor</keyword>
</DOC>